• Publications:
• CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
• Sites of relapse and subsequent therapy in the BR.31 phase 3 study of durvalumab vs placebo in resected stage IB-IIIA NSCLC
• Synopsis: IFCT-1401_synopsis_V3_20210208_IFCT.pdf